News | Contrast Media | November 30, 2018

VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking

NINJA system uses dashboards to display patient data related to exposure criteria in real time

VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking

November 30, 2018 — VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati Children’s research on pediatric nephrotoxic kidney injury and VigiLanz’s capabilities to commercialize a solution for acute kidney injury (AKI) in pediatric patients. Dubbed NINJA, or Nephrotoxic Injury Negated by Just-in-time Action, the solution enables real-time identification and monitoring of patients at risk for AKI due to exposure to nephrotoxic drugs.

“Pediatric acute kidney injury is a serious problem that traditionally could not be identified in real-time, which impacted our ability to identify the patients who most needed treatment,” stated Stuart L. Goldstein, M.D., FAAP, FNKF, director of the Center for Acute Care Nephrology and primary researcher on NINJA.  “By partnering with VigiLanz, Cincinnati Children’s is applying our unprecedented research to a commercially available solution that accurately characterizes pediatric AKI epidemiology, reducing AKI and improving patient outcomes.”

Commercially available to hospitals and health systems focused on mitigating pediatric AKI, NINJA automates the time-consuming manual screening process of evaluating patients for exposure to 57 nephrotoxic medications, imaging contrast dye and recent renal testing. For medications, manual screening is limited to the last 24 hours; the contrast dye evaluation requires reviewing records for the previous seven days to determine if it was received by the patient.

Leveraging NINJA algorithms built into VigiLanz rules, an AKI monitoring dashboard lists all patients that meet the NINJA exposure criteria as well as the criteria that put the patient in the at-risk category. These criteria include medication exposure, serum creatinine data and patient history of AKI. When patients meet at-risk criteria, they are placed on the monitoring list in real time, where they remain until 48 hours after their risk has passed.

The platform also features metric outputs that can be customized with respect to service lines and time periods, while robust reporting tools provide the ability to trend conditions over time via automated run charts. It also enables automatic and customizable data extraction for all metric elements, including inpatient census by location or service line.

For more information: www.vigilanzcorp.com

Related AKI Content

Understanding Contrast-Induced Nephropathy

VIDEO: How to Avoid Acute Kidney Injury in the Cath Lab

VIDEO: Strategies to Avoid Acute Kidney Injury Caused by Cath Lab Contrast

 

Related Content

News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...